Slingshot members are tracking this event:

Sage Therapeutics (SAGE) Announces Initiation of Phase 2 Clinical Development for SAGE-217 in Mood Disorders

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Catalyst Date
Occurred on:
Dec 19, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Sage-217, Mood Disorders, Phase 2